Sarcopenia Market 2024-2034
                     Sarcopenia 
Market Research 
Report 2024-
2034
ABOUT IMARC
International Market Analysis Research and 
Consulting Group is a leading adviser on 
management strategy and market research 
worldwide. We partner with clients in all regions and 
industry verticals to identify their highest-value 
opportunities, address their most critical challenges, 
and transform their businesses.
IMARC’s information products include major market, 
scientific, economic and technological developments 
for business leaders in pharmaceutical, industrial, 
and high technology organizations. Market forecasts 
and industry analysis for biotechnology, advanced 
materials, chemicals, food and beverage, travel and 
tourism, nanotechnology and novel processing 
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable 
insight into the dynamics of companies and markets 
with close cooperation at all levels of the client 
organization. This ensures that our clients achieve2 
unmatchable competitive advantage, build more 
proficient organizations, and secure lasting results.
Report Description and Highlights
Sarcopenia Market Report Overview:
• Report Attribute                       Details
• Base Year                                         2023
• Forecast Years                        2024-2034
• Historical Years                        2018-2023
• Market Size in 2023                       US$ 1.5 Billion
• Market Forecast in 2034               US$ 2.3 Billion
• Market Growth (2024-2034)        4.1%
The report offers a comprehensive analysis of the Sarcopenia market in the United States, EU5 (including Germany, Spain, Italy, France, and 
the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the 
proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance 
of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in 
the report. 3
Report Description and Highlights
This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone 
interested or involved in the Sarcopenia market.
Market Overview:
The 7 major sarcopenia markets reached a value of US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects 
the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.
4
Report Description and Highlights
The sarcopenia market is gaining increasing attention and investment due to a convergence of factors. 
Sarcopenia, characterized by muscle loss and decreased strength, often accompanied by reduced functionality 
in older adults, is at the center of this growing interest. One of the primary drivers fueling the expansion of the 
sarcopenia market is the rise in the aging population. As the proportion of geriatric individuals continues to 
grow, age-related conditions like sarcopenia become more prevalent, leading to a higher demand for 
interventions and treatments. Awareness campaigns and extensive scientific research on muscle decline 
associated with aging are driving interest and funding in the sarcopenia market. This has resulted in the 
development of specialized exercise programs, pharmaceuticals, and nutritional supplements designed to 
alleviate symptoms. Innovations in diagnostic methods, including DXA scans and MRI, have enhanced the 
detection and monitoring of sarcopenia, enabling timely intervention, which is crucial for effective treatment. 
In certain regions, healthcare policies have been revised to encompass treatments for age-related conditions, 
offering financial incentives to individuals seeking treatment.
This policy shift further augments the market potential for sarcopenia products and services. The recent5 
emphasis on preventive healthcare and wellness has created a conducive environment for addressing the 
onset and progression of sarcopenia. 
Report Description and Highlights
Protein supplements and exercise equipment tailored to build muscle mass in older adults are gaining 
popularity. Additionally, the increased utilization of resistance and strength training to treat the condition by 
enhancing muscle protein synthesis and supporting muscular strength is another significant growth-inducing 
factor. Collaborations between academic institutions, healthcare providers, and biotech companies are 
expediting research and product development, which is expected to contribute significantly to the growth of 
the sarcopenia market in the coming years.
Request a Sample Report: https://www.imarcgroup.com/sarcopenia-market/requestsample
6
Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2032
Countries Included:
• United States
• Germany
• France
7
Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Sarcopenia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Sarcopenia market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current Sarcopenia marketed drugs and late-
stage pipeline drugs.
8
Report Description and Highlights
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
View Report TOC, Figures and Tables: https://www.imarcgroup.com/sarcopenia-market
9
Report Description and Highlights
Competitive Landscape With Key Players:
The competitive landscape of the Sarcopenia market has been studied in the report with the detailed profiles 
of the key players operating in the market.
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: 
https://www.imarcgroup.com/request?type=report&id=7323&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as 
a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research 
worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, 
address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for 
business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and 
industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and 
tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. 1
0
Report Description and Highlights
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: [email protected]
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/
1
1
Key Questions Answered in the Report
1. How has the Sarcopenia market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2023 and how are they expected to 
perform till 2034?
3. What was the country-wise size of the Sarcopenia market across the seven major markets in 2023 and 
what will it look like in 2034?
4. What is the growth rate of the Sarcopenia market across the seven major markets and what will be the 
expected growth over the next ten years?
5. What are the key unmet needs in the market?
12
Table of 
Contents
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
14
Table of Contents
4 Sarcopenia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Sarcopenia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
    
Click here to visit the complete table of content with list of figures and tables: 
https://www.imarcgroup.com/sarcopenia-market/toc
15
Partial List Of Our Clients
16
OUR CLIENTS
17
Disclaimer
© 2024 IMARC All Rights Reserved 
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of 
International Market Analysis Research and Consulting (IMARC). No part of this publication may be 
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be 
used in any form or by and means graphic electronic or mechanical, including photocopying, recording, 
taping or by information storage or retrieval, or by any other form, without the express consent of 
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion 
have been based on information and sources believed to be accurate and reliable at the time of 
publishing. International Market Analysis Research and Consulting makes no representation of warranty 
of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability 
whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this 
publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International 
Market Analysis Research and Consulting. All other trademarks used in this publication are registered 
1
trademarks of their respective companies. 8